‘We have very little data on Asian women's health': Why femtech innovation is urgently needed
The research deficit crisis
We only have very little data and research on the female body, even less on Asian women.
- Maaike Steinebach -
The global research deficit in women's health creates particular challenges across Asia. Women weren't required in clinical studies until 1994, and animal testing was conducted exclusively on male animals until 2014.
'Earlier, women were treated like little men. Also, a lot of research was mainly done on white women. Even now, lots of the research is not disaggregated based on sex. So we only have very little data and research on the female body, less on Asian women, African American women, African women and even less than that on mixed-race women,' says Steinebach.
This creates what Steinebach describes as a cascade effect: 'This research gap leads to a lack of knowledge about their unique health needs and creates a care gap—the care women need and what they can get from the existing healthcare system—which in turn results in a treatment gap.' Fertility, mental health and an ageing population
Above Beyond reproductive health, femtech can identify several critical areas, such as mental health support and brain health support
There are several promising areas of opportunity in the femtech space in Asia, and obviously menstruation, reproductive health and maternal care are critical areas that need to be addressed.
But beyond this, there is also a substantial gap in mental health support. 'Mental health support tailored for women, who are two times more prone to depression and mental health issues than men due to their hormones, is increasingly important,' Steinebach says.
She adds that menopause and ageing-related health solutions are massively underserved markets, as women in Asia are now outliving men and their global peers. 'Due to the lack of knowledge and conversation about these topics, many women navigate these life stages without adequate resources.'
Beyond reproductive health, Steinebach identifies critical areas: 'The integration of technology in health education and awareness can empower women to take charge of their health, creating numerous opportunities for innovative startups in the sexual health space (for example HPV), heart health space (globally the no 1 cause of death for women) and brain health space (two-third of all global Alzheimer patients are women).' The economic case
Every dollar invested in women's health generates $3 in GDP.
- Maaike Steinebach -
The business case extends beyond healthcare outcomes. Steinebach presents compelling data to stakeholders: 'I work with governments to show them how every dollar invested in women's health generates $3 in GDP, so taking care of women is not just good for women, but also good for business and the economy.'
This supports investment for corporates looking to 'attract or retain talent or to meet their ESG goals, for insurance companies to provide better-suited products to meet the lifecycle of women.' Opportunity for Hong Kong in the femtech space
Hong Kong's strategic position offers unique advantages in the femtech sector. As a gateway to mainland China and Southeast Asia, locally developed solutions could serve hundreds of millions of women across the region.
'By fostering collaboration among stakeholders, governments, healthcare providers and tech innovators in Asia, we can create a supportive ecosystem that drives positive change in women's health across Asia,' Steinebach says.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Tatler Asia
a day ago
- Tatler Asia
Inside Women's Health in Focus: A global summit driving change in women's healthcare
Women's Health in Focus brought together medical professionals, researchers and wellness enthusiasts at the Asia Society Hong Kong Centre over two intensive days On June 16 and 17, Women's Health in Focus: A Global Summit brought together medical professionals, researchers and wellness enthusiasts at the Asia Society Hong Kong Center. Hosted by Tatler Front & Female Awards nominee Maaike Steinebach and founder of Femtech Future, a boutique advisory firm for women's health and femtech; and Gen.T honouree Anca Griffiths, CEO and co-founder of OM Health Hub, the gathering addressed the blind spot in modern medicine. 'Anca and I are here because we had a dream, where women truly understand their bodies and feel equipped to take control of their health. A dream where companies recognise that supporting women's health isn't a perk, but smart business and the right thing to do. A dream where investors stop calling women's health 'niche' and start seeing it as one of the fastest moving sectors in innovation.' The Women's Health in Focus's opening discussion featured Alyson J McGregor, author of Sex Matters , and Marjorie Jenkins, who exposed the gender bias embedded in contemporary healthcare with precision. Their panel set the tone for an event that refused to accept the status quo. It revealed that women spend 25 per cent more time in poor health than men on average, a gap which, if closed, could add more than US$1 trillion to the global economy annually by 2040. See also : How a billion-dollar dowry led Gigi Chao to fight for everyone's right to wed and why marriage equality in Hong Kong could finally be within reach Photo 1 of 17 Anca Griffiths and Maaike Steinebach (Photo: courtesy of Nicole Burak) Photo 2 of 17 Marjorie Jenkins, Anca Griffiths and Alyson J. McGregor (Photo: courtesy of Nicole Burak) Photo 3 of 17 Kristina Snaith-Lense, Maaike Steinebach and Claire Melwani (Photo: courtesy of Nicole Burak) Photo 4 of 17 Inside the summit (Photo: courtesy of Nicole Burak) Photo 5 of 17 Fiona Nott, Yanie Soo, Sharmeen Shroff and Cassandra Szoeke (Photo: courtesy of Nicole Burak) Photo 6 of 17 Inside the summit (Photo: courtesy of Nicole Burak) Photo 7 of 17 Christopher Asandra, Lindsay Jang, Isabella Daza and Jill Van Vugt (Photo: courtesy of Nicole Burak) Photo 8 of 17 Inside the summit (Photo: courtesy of Nicole Burak) Photo 9 of 17 Iza Calzado Wintle served as the event's emcee (Photo: courtesy of Nicole Burak) Photo 10 of 17 Jen Wannenmacher served as the event's emcee (Photo: courtesy of Nicole Burak) Photo 11 of 17 Anca Griffiths (Photo: courtesy of Nicole Burak) Photo 12 of 17 Sara Jane Ho and Maaike Steinebach (Photo: courtesy of Nicole Burak) Photo 13 of 17 Inside the summit (Photo: courtesy of Nicole Burak) Photo 14 of 17 Elisabeth Sorrentino, Anca Griffiths, Maaike Steinebach and Sarah Vee (Photo: courtesy of Nicole Burak) Photo 15 of 17 Inside the summit (Photo: courtesy of Nicole Burak) Photo 16 of 17 Inside the summit (Photo: courtesy of Nicole Burak) Photo 17 of 17 Inside the summit (Photo: courtesy of Nicole Burak)
Tatler Asia
3 days ago
- Tatler Asia
Razer's Tan Min-Liang and his brother Tan Min-Han are breaking new ground in gaming technology and cancer detection
A CLEAR CALLING Min-Han, in contrast, has charted a more clinical yet equally ambitious course. His work focuses on non‑invasive diagnostics and precision oncology, developing technologies to detect and treat diseases, particularly cancers. 'As a cancer doctor and geneticist, it's heartbreaking to see patients when their cancer is already advanced, as there's often little we can do,' he says. Cancer is a leading cause of death worldwide, with the World Health Organization reporting an estimated 10 million lives lost to it in 2020 alone—roughly one in six deaths. 'And that's 10 million too many,' Min‑Han states. This is the driving force behind Lucence's work to improve patient outcomes through earlier cancer detection and personalised therapy. The company does this through liquid biopsies—simple blood tests that provide a less-invasive alternative to traditional biopsies, which often involve surgery or radiation-based imaging. Lucence achieved a major breakthrough in February 2023, becoming the first Asian-headquartered company to receive coverage for its flagship LiquidHallmark test under Medicare, the US government-funded healthcare programme. The Singapore-developed test provides insights that can inform treatment decisions and track tumour changes over time for 15 different cancers, including lung, breast and colon cancer. 'Doctors can choose treatments that specifically target the unique genetic changes driving the cancer's growth. By matching the right therapy to the individual's tumour, patients can receive more effective care with fewer side effects, improving their overall quality of life,' Min‑Han explains. In May that same year, Lucence launched LucenceInsight, a groundbreaking early cancer detection tool that analyses a single blood sample to screen for indicators of over 50 types of cancer. 'By detecting cancer before symptoms arise, it enables earlier treatment, potentially leading to better outcomes,' says Min-Han. The test is currently available in clinics and screening centres across Singapore and Hong Kong. Earlier this year, Lucence announced a strategic collaboration with Mayo Clinic Laboratories, a leader in diagnostics that operates primarily in the US and has an international presence, to expand access to cutting‑edge cancer testing services globally. Alongside its laboratories in Singapore and Palo Alto in California, Lucence's innovative LiquidHallmark liquid biopsy technology is now accessible worldwide through Mayo Clinic Laboratories and its healthcare partners, enhancing the global landscape of oncology diagnostics for better decision‑making and patient outcomes. 'With the US healthcare sector exceeding US$4 trillion annually, and Medicare covering more than 65 million lives, this move grants us access to a vast patient pool and positions us within a key innovation hub. The [estimated] 1.9 million [new] cancer diagnoses in the US [in 2022] highlights the market's potential,' says Min‑Han. 'This expansion validates our technology and fosters collaborations with leading institutions. Globally, we aim to revolutionise cancer care by democratising diagnostics, potentially impacting the [millions of ] annual cancer deaths worldwide.' Having made significant inroads into the US—the world's largest healthcare market and a hub for leading pharmaceutical companies—Lucence has come a long way since its beginnings in 2016 as a spin-off company for Singapore's Agency for Science, Technology and Research, where Min-Han led a research laboratory for six years. 'Building the technology was just the beginning,' he says. 'Changing the world around it is a life's mission.' One of the key challenges ahead lies in navigating the complex regulatory landscapes of different countries while scaling operations to meet growing demand. To tackle this, Min-Han draws on the steadfast support of his younger brother, Min-Liang, whose keen business insight and investment support have been instrumental to Lucence's growth. 'As an investor in Lucence, I strongly believe in its mission to revolutionise cancer detection and improve patient outcomes,' says Min‑Liang, who regularly connects with the team, offering guidance and support on business strategy, fundraising efforts and technological advancements. He shares that his own journey with Razer—and deep understanding of the power of technology in transforming industries—has taught him 'the importance of fostering innovation and understanding customer needs to create a brand that resonates with a global target audience'. 'Being Min‑Han's brother,' he goes on to say, 'adds another layer to my commitment to Lucence. Witnessing his dedication to this critical cause first‑hand fuels my passion to see the vision come to life. I actively participate in discussions, provide emotional support and celebrate milestones alongside him.' The Tan brothers' approach to innovation is deeply influenced by their upbringing, which emphasised discipline, critical thinking and a thirst for knowledge. These values were instilled in them from an early age by their parents, who prioritised education and encouraged curiosity. 'Our parents emphasised two principles: work hard and be useful to others,' Min-Han shares. 'They did their best to expose me to science, arts and sports, and succeeded in instilling an enduring interest in hiking. I did well in school—topping the national exams at age 12—but often found it more interesting to pursue abstract questions around science and history. I like solving difficult questions, particularly when information is sparse and even conflicting.' Don't miss: Doctor Anywhere founder Lim Wai Mun on creating a blueprint for a sustainable tech‑enabled healthcare company
Tatler Asia
10-06-2025
- Tatler Asia
‘We have very little data on Asian women's health': Why femtech innovation is urgently needed
The research deficit crisis We only have very little data and research on the female body, even less on Asian women. - Maaike Steinebach - The global research deficit in women's health creates particular challenges across Asia. Women weren't required in clinical studies until 1994, and animal testing was conducted exclusively on male animals until 2014. 'Earlier, women were treated like little men. Also, a lot of research was mainly done on white women. Even now, lots of the research is not disaggregated based on sex. So we only have very little data and research on the female body, less on Asian women, African American women, African women and even less than that on mixed-race women,' says Steinebach. This creates what Steinebach describes as a cascade effect: 'This research gap leads to a lack of knowledge about their unique health needs and creates a care gap—the care women need and what they can get from the existing healthcare system—which in turn results in a treatment gap.' Fertility, mental health and an ageing population Above Beyond reproductive health, femtech can identify several critical areas, such as mental health support and brain health support There are several promising areas of opportunity in the femtech space in Asia, and obviously menstruation, reproductive health and maternal care are critical areas that need to be addressed. But beyond this, there is also a substantial gap in mental health support. 'Mental health support tailored for women, who are two times more prone to depression and mental health issues than men due to their hormones, is increasingly important,' Steinebach says. She adds that menopause and ageing-related health solutions are massively underserved markets, as women in Asia are now outliving men and their global peers. 'Due to the lack of knowledge and conversation about these topics, many women navigate these life stages without adequate resources.' Beyond reproductive health, Steinebach identifies critical areas: 'The integration of technology in health education and awareness can empower women to take charge of their health, creating numerous opportunities for innovative startups in the sexual health space (for example HPV), heart health space (globally the no 1 cause of death for women) and brain health space (two-third of all global Alzheimer patients are women).' The economic case Every dollar invested in women's health generates $3 in GDP. - Maaike Steinebach - The business case extends beyond healthcare outcomes. Steinebach presents compelling data to stakeholders: 'I work with governments to show them how every dollar invested in women's health generates $3 in GDP, so taking care of women is not just good for women, but also good for business and the economy.' This supports investment for corporates looking to 'attract or retain talent or to meet their ESG goals, for insurance companies to provide better-suited products to meet the lifecycle of women.' Opportunity for Hong Kong in the femtech space Hong Kong's strategic position offers unique advantages in the femtech sector. As a gateway to mainland China and Southeast Asia, locally developed solutions could serve hundreds of millions of women across the region. 'By fostering collaboration among stakeholders, governments, healthcare providers and tech innovators in Asia, we can create a supportive ecosystem that drives positive change in women's health across Asia,' Steinebach says.
